Mary T. Thistle
Industry Leader & Independent DirectorMs. Mary T. Thistle, CPA, is Independent Director of Aktis Oncology, Inc. Ms. Thistle was Director of Aktis Oncology, Inc. from February 2025. She is Director of Cullinan Therapeutics, Inc. from August 2024. Ms. Thistle serves as an Independent Director of Q32 Bio Inc. since March 25. 2024. She had been an Independent Director at Vigil Neuroscience, Inc. since April 18, 2022 until August 2025. Ms. Thistle has been Independent Director at Entrada Therapeutics, Inc. since May 2021 and as an Industry Leader since May 2022. Ms. Thistle served as Special Advisor at the Bill & Melinda Gates Medical Research Institute since October 2020 until June 2022. She served as Independent Director at Alaunos Therapeutics, Inc. (formerly known as ZIOPHARM Oncology, Inc.) since November 15, 2020 until December 18, 2023. She served as Chief of Staff at Bill & Melinda Gates Medical Research Institute since January 2018 until October 2020. Ms. Thistle served as the Principal Financial & Accounting Officer at Dimension Therapeutics, Inc. since July 28, 2017. Ms. Thistle served as Chief Operating Officer of Dimension Therapeutics, Inc. from December 18, 2016 to 2017, where she directed multiple financing rounds (including the company's IPO), expanded the pipeline through strategic business development transactions and led the sale of Dimension Therapeutics for a significant premium and served as its Chief Business Officer since February 2, 2015 until December 18, 2016. Ms. Thistle served as Senior Vice President of Business Development at Cubist Pharmaceuticals Inc. from January 2014 to 2015. Ms. Thistle joined Cubist Pharmaceuticals Inc. in January 2009 and served as its Vice President of Business Development from 2012 to 2013 and Senior Director of Business Development from 2009 to 2012. She also held leadership positions at ViaCell, Inc. and PerkinElmer Inc. Ms. Thistle served in a variety of senior executive positions at ViaCell, Inc. which was acquired by PerkinElmer LAS in 2007. Ms. Thistle served as Senior Vice President of Business Development at Optimer Pharmaceuticals, Inc. She served as Senior Vice President, Business Development at PerkinElmer after ViaCell was acquired Ms. Thistle served as Senior Vice President of Business Development - ViaCell Reproductive Health at ViaCell, Inc. Ms. Thistle served as General Manager of ViaCell Reproductive Health of Viacell Inc. since OCtober 2004. Ms. Thistle served as Vice President of Viacord Operations of Viacell Inc. since 2002. She served as Vice President of Financial and Corporate Planning & Treasurer at Viacell Inc. since October 2000. Ms. Thistle provided audit, tax and management consulting services to various companies, including serving as consultant to Viacord while at the accounting firm of Yoshita, Croyle & Sokorski from January 1996 to October 2000. From October 1998 to October 1999, she was responsible for all financial aspects, risk management, information technology and human resources of S. R.T, a subsidiary of Thermo Electron. Prior to that, she served various financial management positions at Nashua Corporation, a publicly traded manufacturing company and Deloitte & Touche, a global professional services organization delivering assurance, tax and consulting services. She has been a Non-Executive Director of Enterome SA since July 17, 2017. She has been a Director of Homology Medicines, Inc. since March 15, 2018. She serves as Director of Cocoon Biotech, Inc. Ms. Thistle has a BS in accounting, Business and Management from the University of Massachusetts, Boston (1980 - 1983). She is a graduate of the Women in Bio Boardroom Ready program.
Positions
- Company NameEntrada Therapeutics, Inc.Stock CodeTRDAPositionIndustry Leader & Independent DirectorColleagues
- DDDipal DoshiCEO & Director
- KMKush M. ParmarIndependent Chairman of the Board
- NJNathan J. DowdenPresident & COO
- NSNatarajan SethuramanPresident of Research & Development
- KJKory James WentworthCFO & Treasurer
- JCJared CohenGeneral Counsel
- MTMary T. ThistleIndustry Leader & Independent Director
- PSPeter S. KimDirector
- BGBernhardt G. ZeiherIndependent Director
- Company NameQ32 Bio Inc.Stock CodeQTTBPositionIndependent DirectorColleagues
- JPJodie Pope MorrisonCEO & Director
- MTMark T. IwickiIndependent Chairman of the Board
- LHLee H. KalowskiCFO & President
- SMShelia M. VioletteCo-founder, Chief Scientific Officer & President of Research
- DADavid AppuglieseSenior VP & Head of People
- MMMaria MarzilliChief Business Officer
- KDKathleen D. LaPorteIndependent Director
- MTMary T. ThistleIndependent Director
- DSDavid S. GrayzelIndependent Director
- Company NameAktis Oncology, Inc.Stock CodeAKTSPositionIndependent Director
